Vericel Corporation or Dynavax Technologies Corporation: Who Leads in Yearly Revenue?

Biotech Revenue Race: Vericel vs. Dynavax from 2014 to 2023

__timestampDynavax Technologies CorporationVericel Corporation
Wednesday, January 1, 20141103200028796000
Thursday, January 1, 2015405000051168000
Friday, January 1, 20161104300054383000
Sunday, January 1, 201732700063924000
Monday, January 1, 2018819800090857000
Tuesday, January 1, 201935219000117850000
Wednesday, January 1, 202046551000124179000
Friday, January 1, 2021439442000156184000
Saturday, January 1, 2022722683000164365000
Sunday, January 1, 2023232284000197516000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: Revenue Race from 2014 to 2023

In the dynamic world of biotechnology, Vericel Corporation and Dynavax Technologies Corporation have been on a fascinating revenue journey over the past decade. Starting in 2014, Vericel led with a revenue of approximately $28.8 million, while Dynavax trailed with just over $11 million. However, the tables turned dramatically by 2021, with Dynavax surging ahead, achieving a staggering 3,880% increase to peak at $722.7 million in 2022. Meanwhile, Vericel's growth was steady, reaching $197.5 million in 2023, marking a 585% increase from its 2014 figures.

This revenue race highlights the volatile yet promising nature of the biotech industry, where strategic innovations and market demands can lead to exponential growth. As we look to the future, both companies remain key players, each with unique strengths and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025